CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 25 enrolled
Drug / intervention
Lyumjev with 50% basal rate reduction +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05262387
NCT05262387Phase 1Completed
CompareCT.gov

Effectiveness of a Basal Rate Reduction With LyumjevTM Versus Humalog® on the Protection From Exercise-Induced Hypoglycemia in Individuals With Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion

Eli Lilly and Company·interventional·Posted Mar 2, 2022·Updated Sep 3, 2024

In Brief

A Phase 1 clinical trial evaluating Lyumjev with 50% basal rate reduction, Humalog with 50% basal rate reduction, and 2 other interventions for Diabetes Mellitus, Type 1. Completed, enrolled 25 participants across 1 site.

Detailed Summary

This study will be conducted in participants with type 1 diabetes mellitus on continuous subcutaneous insulin infusion (CSII) or pump therapy to evaluate the effect of LY900014 (Lyumjev) on blood sugar levels during exercise using different approaches on basal rate reduction and following a test meal compared to insulin lispro (Humalog). The study may last up to approximately 10 weeks and may include up to 7 visits.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 1
CountriesCanada
Collaborators--

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedMar 2, 2022
Enrollment StartFeb 14, 2022
Primary CompletionMar 7, 2023
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 4.3 years ago

Interventions

Lyumjev with 50% basal rate reductiondrug

Administered SC.

Humalog with 50% basal rate reductiondrug

Administered SC.

Humalog with 100% basal rate reductiondrug

Administered SC.

Lyumjev with 100% basal rate reductiondrug

Administered SC.